Demand for healthcare products returns as Covid base effect normalises

"We are seeing steady recovery in our healthcare portfolio, which is a higher margin business. We expect healthcare alone to be a ₹5,000 crore business in the near term," Dabur India CEO Mohit Malhotra said while addressing investors. The company's healthcare portfolio includes Chyawanprash, Honitus and Honey. In FY23, Dabur's healthcare business clocked revenue of ₹2,581 crore, more than the ₹1,724 crore in its food and beverage business.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ieB57qm
via IFTTT